top of page
Untitled design (52).png

Benjamin Winograd,
MD, Ph.D.

Chief Medical Officer

Dr. Winograd brings more than 35 years of drug development experience to K36. As Chief Medical Offer he joins the company from Lava Therapeutics, where he led the clinical development program of their Gammabody® pipeline of programs in hematological and solid tumor indications. Prior to that, he was at Celgene, where he most recently served as the clinical research and development therapeutic area head for multiple myeloma and led landmark studies resulting in the registration of lenalidomide (REVLIMID®) and pomalidomide (POMALYST®/Imnovid®) and Abecma®.


Dr. Winograd began his career at the European Organization for Research and Treatment of Cancer (EORTC) and has held positions of increasing responsibility, including Director of Clinical Cancer Research in Europe and U.S. for Bristol-Myers Squibb, VP of Global Medical Affairs in Oncology at Pharmacia, and VP of Global Medical Affairs of Oncology at Schering-Plough. He was instrumental in the early and late development, registration and launching of cancer therapeutics including paclitaxel (Taxol®), irinotecan (Camptosar®), exemestane (Aromasin®), epirubicin (ELLENCE®) and temozolomide (Temodar®). 


Dr. Winograd received his M.D. and Ph.D. from the Technical University of Munich, Germany.

bottom of page